Mother-to-child transmission of HIV-1: Advances and controversies of the twentieth centuries

AIDS Reviews

Volumn 6, Issue 2, 2004, Pages 67-78

  Scarlatti, Gabriella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

HIV; Mother child; Transmission

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR5; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G1B12; LAMIVUDINE; MARKER; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; NEUTRALIZING ANTIBODY; NEVIRAPINE; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; BREAST FEEDING; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE DELETION; GENETIC POLYMORPHISM; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; INTRAUTERINE INFECTION; LONG TERM CARE; LYMPHOCYTE COUNT; META ANALYSIS; MOLECULAR RECOGNITION; MOTHER; NONHUMAN; PERINATAL INFECTION; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SYNCYTIUM; VIRUS CHARACTERIZATION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; BREAST FEEDING; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SELECTION (GENETICS);

EID: 4344649768     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organization (WHO). AIDS Epidemic Update 2003. www.unaids.org.
2. UNAIDS WHO, Occasional Paper. 1999.
3. De Cock K, Fowler M, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000;283:1175-82.
4. Scarlatti G. Paediatric Human Immunodeficiency Virus Type 1 infection. Lancet 1996;348:863-8.
5. Dunn D, Newell M, Ades A, Peckham C. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992;340:585-8.
6. Mayaux M, Teglas J, Mandelbrot L, et al. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France. J Pediatr 1997;131:857-62.
7. Menu E, Scarlatti G, Barre-Sinoussi F, et al. Mother-to-child transmission of HIV: developing integration of healthcare programs with clinical, social and basic research studies. Report of the International Workshop held at Chobe Marina Lodge, Kasane, Botswana, 21-25 January 2003. Acta Paediatr 2003;92:1343-8.
8. Mofenson L, McIntyre J. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 2000; 355:2237-44.
9. Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999;354:795-802.
10. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 2000;343:982-91.
11. Rouzioux C, Costagliola D, Burgard M, et al. Timing of mother-to-child transmission depends on maternal status. AIDS 1993; 7:49-52.
12. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomized, double-blind, placebo-controlled trial. Lancet 2002;359:1178-86.
13. Lallemant M, Jourdain G, Le Coeur S, et al. A randomized, double-blind trial assessing the efficacy of single-dose perinatal Nevirapine added to a standard Zidovudine regimen for the prevention of mother-to-child transmission of HIV-1 in Thailand. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco 2004.
14. World Health Organization (WHO). Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings. Expert consultation, Geneva, 5-6 February 2004. www.hoint/3by5/arv′tct/en/ 2004.
15. Leroy V, Karon J, Alioum A, et al. Postnatal transmission of HIV-1 after a maternal short-course zidovudine peripartum regimen in West Africa. AIDS 2003;17:1493-501.
16. Jamieson D, Sibailly T, Sadek R, et al. HIV-1 viral load and other risk factors for mother-to-child transmission of HIV-1 in a breast-feeding population in Cote d'Ivoire. J Acquir Immune Defic Syndr 2003;34:430-6.
17. Eshleman S, Mracna M, Guay L, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-7.
18. Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following single-dose Nevirapine in a PMTCT cohort, In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco 2004.
19. Cunningham C, Chaix M, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002; 186:181-8.
20. Eshleman S, Guay L, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004;35:126-30.
21. Nolan M, Fowler M, Mofenson L. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr 2002;30:216-29.
22. Jourdain G, Ngo-Giang-Huong N, Tungyai P, et al. Exposure to intrapartum single-dose Nevirapine and subsequent maternal 6-month response to NNRTI-based regimens. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco 2004.
23. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-9.
24. Barret B, Tardieu M, Rustin P, et al, Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003;17:1769-85.
25. The Perinatal Safety Reviews Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000;25:261-8.
26. Thorne C, Newell M, and European Collaborative Study. Pregnancy outcome in ART-treated HIV-infected women in Europe. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco 2004.
27. Jackson J, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomized trial. Lancet 2003;362:859-68.
28. Leroy V, Karon J, Alioum A, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa, AIDS 2002;16:631-41.
29. Moodley D, Moodley J, Coovadia H, et al, A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003;187:725-35.
30. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000;283:1167-74.
31. John-Stewart G, Mbori-Ngacha D, Ekpini R, et al. Breastfeeding and transmission of HIV-1. J Acquir Immune Defic Syndr 2004;35:196-202.
32. Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai W, Coovadia H. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS 2001;15:379-87.
33. Nduati R, Richardson B, John G, et al. Effect of breastfeeding on mortality among HIV-1 infected women: a randomized trial. Lancet 2001;357:1651-6.
34. Rollins N, Meda N, Becquet R, et al. Preventing postnatal transmission of HIV-1 through breastfeeding: modifying infant feeding practices. J Acquir Immune Defic Syndr 2004;35:188-95.
35. Gaillard P, Fowler M, Dabis F, et al. Use of antiretroviral drugs to prevent HIV-1 transmission through breastfeeding: from animal studies to randomized clinical trials. J Acquir Immune Defic Syndr 2004;35:178-87.
36. Sperling R, Shapiro D, Coombs R, et al. Maternal viral load, Zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9.
37. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet 1992;339:1007-12.
38. John G, Nduati R, Mbori-Ngacha D, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206-12.
39. Leroy V, Montcho C, Manigart O, et al. Maternal plasma viral load, zidovudine and mother-to-child transmission of HIV-1 in Africa: DIT-RAME ANRS 049a trial. AIDS 2001;15:517-22.
40. Montano M, Russell M, Gilbert P, et al. Comparative prediction of perinatal human immunodeficiency virus type 1 transmission, using multiple virus load markers. J Infect Dis 2003;188:406-13.
41. Mock P, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand, Bangkok Collaborative Perinatal HIV Transmission Study Group. AIDS 1999;13:407-14.
42. Semba R, Kumwenba N, Hoover D, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999;180:93-8.
43. Pillay K, Coutsoudis A, York D, Kuhn L, Coovadia H. Cell-free virus in breast milk of HIV-1-seropositive women. J Acquir Immune Defic Syndr 2000;24:330-6.
44. Rousseau C, Nduati R, Richardson B, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 2003; 187:741-7.
45. Fawzi W, Msamanga G, Spiegelman D, et al. Transmission of HIV-1 through breastfeeding among women in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 2002;31:331-8.
46. Cao Y, Krogstad P, Korber B, et al. Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant. Nature Med 1997;3:549-52.
47. Contopoulos-Ioannidis D, Ioannicis J, Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission: a meta-analysis. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:126-35.
48. Devash Y, Calvelli T, Wood D, Reagan K, Rubinstein A. Vertical transmission of human immunodeficiency virus is correlated with the absence of high affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci USA 1990;87:3445-9.
49. Halsey N, Markham R, Wahren B, Boulos R, Rossi P, Wigzell H. Lack of association between maternal antibodies to V3 loop peptides and maternal-infant transmission. J Acquir Immune Defic Syndr 1992;5:153-7.
50. Rossi P, Moschese V, Broliden P, et al. Presence of antibodies to HIV-1gp12O env epitopes correlates with uninfected status of the children born to seropositive mothers. Proc Natl Acad Sci USA 1989;86:8055-8.
51. Ugen K, Goedert J, Boyer J, et al. Vertical transmission of human immunodeficiency virus (HIV) infection: reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest 1992;89:1923-30,
52. Lallemant M, Baillou A, Lallemant-Coeur S, et al. Maternal anti-body response at delivery and perinatal transmission of human immunodeficiency virus type 1 in African women. Lancet 1994;343:1001-5.
53. Guevara H, Casseb J, Zijenah L, et al. Maternal HIV-1 antibody and vertical transmission in subtype C virus infection. J Acquir Immune Defic Syndr 2002;29:435-40.
54. Scarlatti G, Albert J, Rossi P, et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993;168:207-10.
55. Kliks S, Wara D, Landers D, Levy J. Features of HIV-1 that could influence maternal-child transmission. JAMA 1994;272:467-74.
56. Husson R, Lan Y, Kojima E, Venzon D, Mitsuya H, McIntosh K. Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. J Pediatr 1995;126:865-71.
57. Bongertz V, Costa C, Veloso V, et al. Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity. Scand J Immunol 2001;53:302-9.
58. Lathey J, Tsou J, Brinker K, Hsia K, Meyer W 3rd Spector S. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. J Infect Dis 1999;180:344-50.
59. Hengel R, Kennedy M, Steketee R, et al. Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS Res Hum Retroviruses 1998;14:475-81.
60. Louisirirotchanakul S, Beddows S, Cheingsong R, et al. Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand. J Acquir Immune Defic Syndr 1999;21:259-65.
61. Van de Perre P, Simonon A, Hitimana D, et al. Infective and anti-infective properties of breast milk from HIV-1 -infected women. Lancet 1993;341:914-8.
62. Alfsen A, Bouguyon E, Bomsel M. Secretory IgA specific for a conserved epitope on gp4l envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001;166:6257-65.
63. Bomsel M, Heyman M, Hocini H, et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dlgA or IgM. Immunity 1998;9:277-87.
64. Baba T, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-6.
65. Ferrantelli F, Hofmann-Lehmann R, Rasmussen R, et al, Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003; 17:301-9.
66. Hofmann-Lehmann R, Vlasak J, Rasmussen R, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001;75:7470-80.
67. Ruprecht R, Ferrantelli F, Kitabwalla M, Xu W, McClure H. Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine 2003;21:3370-3.
68. Sutthent R, Foongladda S, Chearskul S, et al, V3 sequence diversity of HIV-1 subtype E in infected mothers and their infants. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:323-31.
69. Ahmad N, Baroudy B, Baker R, Chappey C. Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol 1995;69:1001-12.
70. Zhang Y, Dragic T, Cao Y, et al. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J Virol 1998;72:9337-44.
71. Seidlein L, Plaeger S, Dickover R, Krogstad P, Stiehm E, Bryson Y. Primary human immunodeficiency virus type 1 infection during pregnancy associated with transmission of SI/MT-2 cell tropic virus and precipitous loss of CD4 cells in mother and infant. Pediatr Infect Dis J 1998;17:528-30.
72. Van't Wout A, Kootstra N, Mulder-Kampinga G, et al. Macrophagetropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994;94:2060-7.
73. Tscherning-Casper C, Vodros D, Menu E, et al. Coreceptor usage of HIV-1 isolates representing different genetic subtypes obtained from pregnant Cameroonian women. European network for in utero transmission of HIV-1. J Acquir Immune Defic Syndr 2000;24:1-9.
74. Scarlatti G, Hodara V, Rossi P, et al. Transmission of human immunodeficiency virus type 1 (HIV-1) from mother-to-child correlates with viral phenotype. Virology 1993;197:624-9.
75. Ometto L, Zanchetta M, Mainardi M, et al. Coreceptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission. AIDS 2000;14:1721-9.
76. Ometto L, Zanotto C, Maccabruni A, et al. Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission. AIDS 1995;9:427-34.
77. Salvatori F, Scarlatti G. HIV type 1 chemokine receptor usage in mother-to-child transmission. AIDS Res Hum Retroviruses 2001;17:925-35.
78. Casper C, Clevestig P, Carlenor E, et al. Link between the X4 phenotype in human immunodeficiency virus type 1-infected mothers and their children, despite the early presence of R5 in the child. J Infect Dis 2002;186:914-21.
79. Workshop Report from the European Commission (DG XII JNCO DC) and the Joint United Nations Programme on HIV/ADS. HIV-1 subtypes: implication for epidemiology, pathogenicity, vaccines and diagnostics. AIDS 1997;11:17-36.
80. Karlsson I, Antonsson L, Shi Y, et al. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 2003;17:2561-9.
81. Ioannidis J, Contopoulos-Ioannicis D, Rosenberg P, et al. Effects of CCR5-delta32 and CCR2-641 alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS 2003; 17:1631-8.
82. Huang Y, Paxton W, Wolinsky S, et al, The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996;2:1240-3.
83. Teglas J, N'Go N, Burgard M, et al. CCR2B-641 chemokine receptor allele and mother-to-child HIV-1 transmission or disease progression in children. French pediatric HIV infection study group. J Acquir Immune Defic Syndr 1999;22:267-71.
84. John G, Rousseau C, Dong T, et al. Maternal SDF1 3'A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission. J Virol 2000;74:5736-9.
85. Gaillard P, Verhofstede C, Mwanyumba F, et al. Exposure to HIV-1 during delivery and mother-to-child transmission. AIDS 2000;14:2341-8.
86. Jain L, Vidyasagar D, Xanthou M, Ghai V, Shimada S, Blend M. In vivo distribution of human milk leucocytes after ingestion by newborn baboons. Arch Dis Child 1989;64:930-3.
87. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nature Med 1997;3:142-7.
88. Fotopoulos G, Harari A, Michetti P, Trono D, Pantaleo G, Kraehenbuhl J. Transepithelial transport of HIV-1 by M cells is receptor-mediated. Proc Natl Acad Sci USA 2002;99:9410-4.
89. Rescigno M, Urbano M, Valzasina B, at al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001;2:361-7.
90. Geijtenbeek T, Van Duijnhoven G, Van Vliet S, et al. Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J Biol Chem 2002;277:11314-20.
91. De Rossi A, Masiero S, Giaquinto C, at al. Dynamics of viral replication in infants with vertical acquired human immunodeficiency virus type 1 infection. J Clin Invest 1996;97:323-30.
92. Zachar V, Thomas R, Jones T, Goustin A. Vertical transmission of HIV: detection of proviral DNA in placental trophoblast.AIDS 1994;8:129-30.
93. Lee B, Popek E, at al. Inflammatory cytokine expression is correlated with the level of human immunodeficiency virus (HIV) transcripts in HIV-infected placental trophoblastic cells. J Virol 1997;71:3628-35.
94. Backé E, Jiménez E, Unger M, Schäfer A, Jauniaux E, Vogel M. Demonstration of HIV-1 infected cells in human placenta by in situ hybridization and immunostaining. J Clin Pathol 1992;45:871-4.
95. Mattern C, Murray K, Jensen A, Farzadegan H, Pang J, Modin J. Localization of human immunodeficiency virus core antigen in term placentas. Pediatrics 1992;89:207-9.
96. Lewis S, Reynolds-Kohler C, Fox H, Nelson J. HIV-1 in trophoblastic and villous Hofbauer cells, and hematologic precursors in eight week fetuses. Lancet 1990;335:565.
97. Sprecher S, Soumenkoff G, Puissant F, Degueldre M, Vertical transmission of HIV in 15-week fetus. Lancet 1986;2:88-9.
98. Ehrnst A, Lindgren S, Dictor M, et al, HIV in pregnant women and their offspring: evidence for late transmission. Lancet 1991;338:203-7.
99. Tscherning-Casper C, Papadogiannakis N, Anvret M, et al. The trophoblastic epithelial barrier is not infected in full-term placentae of human immunodeficiency virus-seropositive mothers undergoing antiretroviral therapy. J Virol 1999;73:9673-8.
100. Menu E, Mbopi-Keou F, Lagaye S, et al. Selection of maternal human immunodeficiency virus type 1 variants in human placenta. European network for in utero transmission of HIV-1. J Infect Dis 1999;179:44-51.
101. De Andreis C, Simoni G, Rossella G, et al. HIV-1 proviral DNA polymerase chain reaction detection in chorionic villi after exclusion of maternal contamination by variable number of tandem repeats analysis. AIDS 1996;10:711-5.
102. Mognetti B, Moussa M, Croitoru J, at al. HIV-1 coreceptor expression on trophoblastic cells from early placentas and permissivity to infection by several HIV-1 primary isolates. Clin Exp Immunol 2000; 119:486-92.
103. Geijtenbeek T, Van Vliet S, Van Duijnhoven G, Figdor C, Van Kooyk Y. DC-SIGN, a dendritic cell-specific HIV-1 receptor present in placenta that infects T-cells in trans-a review. Placenta 2001;22(SupplA): 19-23.
104. Arias R, Muñoz L, Muñoz-Fernández M. Transmission of HIV-1 infection between trophoblast placental cells and T-cells take place via an LFA-1-mediated cell to cell contact. Virology 2003; 307:266-77.
105. Lagaye S, Derrien M, Menu E, et al. Cell-to-cell contact results in a selective translocation of maternal human immunodeficiency virus type 1 quasispecies across a trophoblastic barrier by both transcytosis and infection. J Virol 2001;75:4780-91.
106. Verhoeff F, Brabin B, Hart C, Chimsuku L, Kazembe P, Broadhead R. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop Med Int Health 1999;4:5-12.
107. Inion I, Mwanyumba F, Gaillard P, et al. Placental malaria and perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 2003;188:1675-8.
108. Mwapasa V, Rogerson S, Molyneux M, et al. The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS 2004;18:1051-9.
109. Kapiga S, Bang H, Spiegelman D, et al. Correlates of plasma HIV-1 RNA viral load among HIV-1-seropositive women in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr 2002;30:316-23.
110. Tkachuk A, Moormann A, Poore J, et al. Malaria enhances expression of CC chemokine receptor 5 on placental macrophages. J Infect Dis 2001;183:967-72.
111. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al, The effects of placental malaria on mother-to-child HIV transmission in Rakai, Uganda. AIDS 2003;17:2539-41.
112. Scarlatti G, Leitner T, Halapi E, et al. Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci USA 1993;90:1721-5.
113. Wolinsky S, Wilke C, Korber B, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992;255:1134-7.
114. Wilson C, Brown R, Korber B, et al. Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the Ariel project for the prevention of transmission of HIV from mother to infant. J Virol 1999;73:3975-85.
115. Goulder P, Brander C, Tang Y, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001;412:334-8.
116. Leslie A, Pfafferoft K, Chetty P, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004;10:282-9.
117. Briant L, Wade C, Puel J, Leigh Brown A, Guyader M. Analysis of envelope sequence variants suggests multiple mechanisms of mother-to-child transmission of human immunodeficiency virus type 1. J Virol 1995;69:3778-88.
118. Renjifo B, Fawzi W, Mwakagile D, et al, Differences in perinatal transmission among human immunodeficiency virus type 1 geno-types. J Hum Virol 2001;4:16-25.
119. Zhang H, Orti G, Du Q, et al. Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C mother-to-child transmission. AIDS Res Hum Retroviruses 2002;18:1415-23.
120. Verhofstede C, Demecheleer E, De Cabooter N, et al. Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. J Virol 2003;77:3050-7.
121. Dickover R, Garratty E, Plaeger S, Bryson Y. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol 2001;75:2194-203.
122. Murray M, Embree J, Ramdahin S, Anzala A, Njenga S, Plummer F. Effect of human immunodeficiency virus (HIV) type 1 viral geno-type on mother-to-child transmission of HIV-1. J Infect Dis 2000; 181:746-9.
123. Sagar M, Lavreys L, Baeten J, et al. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol 2003;77:12921-6.
124. Sagar M, Lavreys L, Baeten J, et al. Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS 2004;18:615-9.